752222-81-4

Basic information

• Product Name: 2,4(1H,3H)-Pyrimidinedione, 5,6-diamino-1-ethyl-3-propyl- (9CI)
• Synonyms: 2,4(1H,3H)-Pyrimidinedione, 5,6-diamino-1-ethyl-3-propyl- (9CI);5,6-diaMino-1-ethyl-3-propylpyriMidine-2,4(1H,3H)-dione;1-Ethyl-3-propyl-5,6-diaminouracil
• CAS NO: 752222-81-4
• Molecular Formula: C₉H₁₆N₄O₂
• Molecular Weight: 212.24894
• Product Categories: ETHYL;ALCOHOL
• Mol File: 752222-81-4.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,4(1H,3H)-Pyrimidinedione, 5,6-diamino-1-ethyl-3-propyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4(1H,3H)-Pyrimidinedione, 5,6-diamino-1-ethyl-3-propyl- (9CI)(752222-81-4)
• EPA Substance Registry System: 2,4(1H,3H)-Pyrimidinedione, 5,6-diamino-1-ethyl-3-propyl- (9CI)(752222-81-4)

Safety Data

• Hazardous Substances Data: 752222-81-4(Hazardous Substances Data)

Usage

Description

2,4(1H,3H)-Pyrimidinedione, 5,6-diamino-1-ethyl-3-propyl(9CI) is a pyrimidinedione derivative with a molecular formula of C9H15N5O2. It features amino groups at the 5 and 6 positions and is known for its biological activity. This chemical compound may be of interest for pharmaceutical research due to its structure, which suggests potential as an intermediate in the synthesis of pharmaceuticals or other organic compounds. However, its specific properties and potential applications are not widely documented, and further research is needed to fully understand its uses.

Uses

Used in Pharmaceutical Research:
2,4(1H,3H)-Pyrimidinedione, 5,6-diamino-1-ethyl-3-propyl(9CI) is used as a chemical intermediate for the synthesis of pharmaceuticals or other organic compounds due to its unique structure and biological activity. Its potential applications in this field are currently under investigation, and further research is required to explore its full potential.

Upstream product

• 752222-78-9 N'-(3-ethyl-1,2,3,6-tetrahydro-2,6-dioxopyrimidin-4-yl)-N,N-dimethylformamidine 
• 41862-09-3 1-ethyl-6-aminouracil 
• 879328-64-0 6-[1-aza-2-(dimethylamino)vinyl]-1-ethyl-3-propyl-1,3-dihydropyrimidine-2,4-dione 
• 752222-79-0 6-amino-1-ethyl-5-nitroso-3-propylpyrimidine-2,4(1H,3H)-dione 

Downstream Products

• 1019778-50-7 8-(1-benzyl-1H-pyrazol-4-yl)-3-ethyl-1-propyl-1H-purine-2,6(3H,7H)-dione 
• 1188541-14-1 4-{3-[4-(3-ethyl-2,6-dioxo-1-propyl-2,3,6,7-tetrahydro-1H-purin-8-yl)pyrazol-1-yl]prop-1-ynyl}benzoic acid 
• 1188541-09-4 3-{3-[4-(3-ethyl-2,6-dioxo-1-propyl-2,3,6,7-tetrahydro-1H-purin-8-yl)pyrazol-1-yl]prop-1-ynyl}benzoic acid 
• 1188541-12-9 3-ethyl-1-propyl-8-{1-[3-(4-trifluoromethoxyphenyl)prop-2-ynyl]-1H-pyrazol-4-yl}-3,7-dihydropurine-2,6-dione 
• 1188541-00-5 3-ethyl-1-propyl-8-{1-[3-(3-trifluoromethoxyphenyl)prop-2-ynyl]-1H-pyrazol-4-yl}-3,7-dihydropurine-2,6-dione 
• 1188541-01-6 3-ethyl-1-propyl-8-{1-[3-(4-trifluoromethylphenyl)prop-2-ynyl]-1H-pyrazol-4-yl}-3,7-dihydropurine-2,6-dione 
• 1188541-08-3 3-ethyl-8-{1-[3-(4-fluorophenyl)prop-2-ynyl]-1H-pyrazol-4-yl}-1-propyl-3,7-dihydropurine-2,6-dione 
• 1188541-04-9 3-ethyl-8-{1-[3-(3-fluorophenyl)prop-2-ynyl]-1H-pyrazol-4-yl}-1-propyl-3,7-dihydropurine-2,6-dione 
• 1073496-62-4 C₂₀H₂₄N₆O₃ 
• 1073496-71-5 C₂₀H₂₃FN₆O₃ 
• 752222-82-5 N-(6-amino-1-ethyl-2,4-dioxo-3-propyl(1,3-dihydropyrimidin-5-yl))(1-{[3-(trifluoromethyl)phenyl]methyl}-pyrazol-4-yl)carboxamide 

Relevant articles and documents

Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension

This disclosure relates generally to treating patients having pulmonary hypertension, or symptoms associated therewith, by administering a therapeutically effective amount of an A2B receptor antagonist to the patient.

METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS

The invention is related to methods of preventing and treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical compositions for use in the method.

METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS

The present invention relates to methods of preventing airway remodeling using A2B adenosine receptor antagonists. This invention finds utility in the treatment and prevention of asthma, COPD, pulmonary fibrosis, emphysema, and other pulmonary diseases. The invention also relates to pharmaceutical compositions for use in the method.